Hepatocellular carcinoma: Agents and concepts for preventing recurrence after curative treatment
Hans J. Schlitt, Andreas A. Schnitzbauer – 17 August 2011 – Key Points
Immunosuppression in pediatric liver transplantation: Are little people different?
Anil Dhawan – 17 August 2011 – Key Points
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Göran B. Klintmalm, Gary L. Davis, Lewis Teperman, George J. Netto, Kenneth Washburn, Stephen M. Rudich, Elizabeth A. Pomfret, Hugo E. Vargas, Robert Brown, Devin Eckhoff, Timothy L. Pruett, John Roberts, David C. Mulligan, Michael R. Charlton, Thomas G. Heffron, John M. Ham, David D. Douglas, Linda Sher, Prabhakar K. Baliga, Milan Kinkhabwala, Baburao Koneru, Michael Abecassis, Michael Millis, Linda W. Jennings, Carlos G.
The immunoreactive patient: Rejection and autoimmune disease
John O'Grady – 17 August 2011 – Key Points
Ductular reactions in human liver: Diversity at the interface
Annette S. H. Gouw, Andrew D. Clouston, Neil D. Theise – 16 August 2011 – Interest in hepatic ductular reactions (DRs) has risen in recent years because of a greater appreciation of their potential roles in regeneration, fibrogenesis, and carcinogenesis. However, confusion exists because there is significant, but often unappreciated diversity at the tissue, cellular, and subcellular levels in DRs of different diseases and stages of disease.
Pathogen‐ or damage‐associated molecular patterns during nonalcoholic fatty liver disease development
Anna Alisi, Rita Carsetti, Valerio Nobili – 16 August 2011
Pentoxifylline for steatohepatitis: Magic bullet or smoking gun?
Richard K. Sterling, Arun J. Sanyal – 16 August 2011
Late‐onset carbamoyl phosphate synthetase 1 deficiency in an adult cured by liver transplantation
Timothy R. Bates, Barry D. Lewis, John R. Burnett, Kenji So, Andrew Mitchell, Luc Delriviere, Gary P. Jeffrey – 11 August 2011 – Urea cycle disorders (UCDs) are rare causes of hyperammonemic encephalopathy in adults. Most UCDs present in childhood and, if unrecognized, are rapidly fatal. Affected individuals who survive to adulthood may remain undiagnosed because of clinicians' unawareness of the condition or atypical presentations. We describe the case of a 49‐year‐old man who initially presented with a stroke and developed hyperammonemic encephalopathy over a period of 8 months.
Optimizing cost‐effectiveness in perioperative care for liver transplantation: A model for low‐ to medium‐income countries
Karina Rando, Claus U. Niemann, Pilar Taura, John Klinck – 11 August 2011 – Although liver transplantation (LT) is a highly effective treatment, it has been considered too costly for publicly funded health systems in many countries with low to medium average incomes. However, with economic growth and improving results, some governments are reconsidering this position. Cost‐effectiveness data for LT are limited, especially in perioperative care, and the techniques and costs vary widely between centers without overt differences in outcomes.
Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection
Norman M. Kneteman, Sonal Asthana, Jamie Lewis, Chelcey Dibben, Donna Douglas, Mahra Nourbakhsh, Lorne J. Tyrrell, Garry Lund – 11 August 2011 – Cyclosporine A (CSA) has potent effects against hepatitis C virus (HCV) in vitro, but its clinical efficacy after liver transplantation (LT) is uncertain. We evaluated the impact of CSA and tacrolimus (TAC) with or without concomitant interferon (IFN) therapy on serum HCV titers in a chimeric mouse model of HCV infection. Six groups of HCV‐infected mice received only the vehicle, IFN, CSA, CSA and IFN, TAC, or TAC and IFN for 4 weeks.